期刊文献+

2-甲基-3-氨基-5-硝基吡啶的合成研究

A Synthesis Method of 2-methyl-3-Amino-5-nitropyridine
下载PDF
导出
摘要 硝基吡啶类化合物广泛用于有机合成,特别是杂环药物及细胞因子抑制剂的合成。以粘溴酸为原料,分别经与亚硝酸钠反应、与3-氨基巴豆酸乙酯环合、水解,与DPPA反应、脱保护等五步反应最终得到目标产物2-甲基-3-氨基-5-硝基吡啶。此方法仅需要最后一步进行柱纯化,操作简单,后处理方便,总收率为9.1%。 Nitropyridine compound is widely used in organic synthesis,especially in heterocyclic drugs and cytokine inhibitors.Mucobromic acid as raw material is chosed,achieved the target compound in five steps which are respectively reaction with sodium nitrite,cyclization,hydrolysis,reaction with DPPA and deprotection.The method is simple.The total yield is 9.1%.
机构地区 同济大学化学系
出处 《科学技术与工程》 2011年第8期1841-1843,共3页 Science Technology and Engineering
关键词 粘溴酸 抑制剂 硝基吡啶 DPPA mucobromic acid inhibitor nitropyridine DPPA
  • 相关文献

参考文献4

二级参考文献33

  • 1Okuda K,Weisberg E,Gilliland DG,et al.ARG tyrosine kinase activity is inhibited by STI571[J].Blood,2001,97 (8):2440-2448.
  • 2Druker BJ,Tamura S,Buchdunger E,et al.Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells[J].Nat Med,1996,2 (5):561-566.
  • 3Deininger MW,Goldman JM,Lydon N,et al.The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells[J].Blood,1997,90(9):3691-3698.
  • 4Schindler T,Bornmann W,Pellicena P,et al.Structural mechanism for STI-571 inhibition of abelson tyrosine kinase[J].Science,2000,289 (5486):1938-1942.
  • 5Blagosklonny MV.STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'[J].Leukemia,2002,16 (4):570-572.
  • 6Luzzatto L,Frassoni F,Melo JV.Imatinib:can one outwit chronic myeloid leukemia?[J].Haematologica,2002,87(9):898-901.
  • 7Shah NP,Nicoll JM,Nagar B,et al.Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia[J].Cancer Cell,.2002,2(2):117-125.
  • 8Weisberg E,Manley PW,Breitenstein W,et al.Characterization of AMN107,a selective inhibitor of native and mutant Bcr-Abl[J].Cancer Cell,2005,7 (2):129-141.
  • 9O'Hare T,Walters DK,Stoffregen EP,et al.In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants[J].Cancer Res,2005,65 (11):4500-4505.
  • 10Golemovic M,Verstovsek S,Giles F,et al.AMN107,AMN107,a novel aminopyrimidine inhibitor of Bcr-Abl,has in vitro activity against imatinib-resistant chronic myeloid leukemia[J].Clin Cancer Res,2005,11 (13):4941-4947.

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部